Scarica l'app Stockscreener
143.62
4.42%
6.08
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$137.54
Aprire:
$137.93
Volume 24 ore:
332.29K
Relative Volume:
0.87
Capitalizzazione di mercato:
$4.16B
Reddito:
$290.51M
Utile/perdita netta:
$89.16M
Rapporto P/E:
48.03
EPS:
2.99
Flusso di cassa netto:
$119.18M
1 W Prestazione:
+4.56%
1M Prestazione:
-3.07%
6M Prestazione:
-5.09%
1 anno Prestazione:
-22.12%
Intervallo 1D:
$137.93
$144.23
Intervallo di 1 settimana:
$132.31
$144.23
Portata 52W:
$122.80
$207.84
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Confronta KRYS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
143.62 | 3.98B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-05 | Iniziato | Jefferies | Buy |
| 2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-18 | Iniziato | BofA Securities | Buy |
| 2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-06-04 | Iniziato | Evercore ISI | Outperform |
| 2019-09-24 | Iniziato | Goldman | Neutral |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-30 | Iniziato | Guggenheim | Buy |
| 2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
Evercore Maintains Krystal Biotech(KRYS.US) With Buy Rating, Maintains Target Price $200 - 富途牛牛
Astrana Health And 2 Insider Favorites For High Growth - simplywall.st
Krystal Biotech’s Earnings Call: Strong Growth Amid Challenges - MSN
Krystal Biotech, Inc. (NASDAQ:KRYS) Q2 2025 Earnings Call Transcript - MSN
Quoin (QNRX) Q2 Loss Beats Estimates - The Motley Fool
Krystal Biotech sees global VYJUVEK expansion and expects Q3 revenue dip before renewed growth - MSN
Palmoplantar Keratoderma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Sol-Gel Technologies Ltd., Krystal Biotech Inc. - Barchart.com
Local biotech co-founder named to Forbes 50 Over 50 - MSN
Krystal Biotech Analyst Ratings: Bullish Sentiment with 6 Buy Ratings - AInvest
Krystal Biotech Q2 Earnings Call: Strong Growth Amid Challenges - AInvest
Krystal Biotech Shares Rise After Q2 Earnings, Revenue Beat Expectations - MSN
Krystal Biotech: Citigroup maintains Neutral, PT down to $166 from $176. - AInvest
Reassessing Krystal Biotech: Navigating Short-Term Volatility to Unlock Long-Term Value - AInvest
Krystal Biotech price target lowered to $182 from $192 at BofA - Yahoo Finance
A Quick Look at Today's Ratings for Krystal Biotech(KRYS.US), With a Forecast Between $166 to $240 - 富途牛牛
KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook - Nasdaq
Exploring 3 High Growth Tech Stocks In The US Market - Yahoo Finance
Krystal Biotech Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Krystal Biotech Inc (KRYS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Krystal Biotech Reports Strong Q2 2025 Results - TipRanks
Krystal Biotech price target lowered to $166 from $176 at Citi - TipRanks
Krystal Biotech stock price target lowered to $182 at BofA on growth concerns - Investing.com Nigeria
Krystal Biotech Plummets 14.04% on Record $290M Trading Volume Ranks 382nd Amid Surging Revenue and Regulatory Momentum - AInvest
Krystal Biotech Exceeds Q2 2025 Earnings Estimates with $96 Million Revenue, $1.33 EPS - AInvest
Krystal Biotech sees revenue growth but anticipates dip due to summer vacations - The Business Journals
Contradictions Unveiled: Krystal Biotech's Q2 2025 Earnings Call Reveals Conflicting Insights on VYJUVEK Sales and Market Strategy - AInvest
Krystal Biotech, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech: Strong Financial Performance and Strategic Global Expansion Justify Buy Rating - TipRanks
Krystal Biotech shares fall 12.71% intraday after missing Q2 earnings estimates. - AInvest
Krystal Biotech Q2 2025 slides: VYJUVEK drives growth amid global expansion - Investing.com Canada
Earnings call transcript: Krystal Biotech Q2 2025 beats forecasts, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Krystal Biotech Q2 2025 beats forecasts, stock dips - Investing.com Canada
Krystal Biotech, Inc. (KRYS) Tops Q2 Earnings and Revenue Estimates - sharewise.com
Transcript : Krystal Biotech, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
Krystal Biotech shares jump as Q2 results exceed expectations By Investing.com - Investing.com India
Krystal Biotech shares jump as Q2 results exceed expectations - Investing.com
Krystal Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Krystal Biotech Grows Revenue On VYJUVEK’s Expanding Global Reach - Finimize
Krystal Biotech Q2 Earnings, Revenue Rise - MarketScreener
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q2 Revenue $96.0M, vs. FactSet Est of $92.0M - MarketScreener
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results - TradingView
Krystal Biotech earnings beat by $0.07, revenue topped estimates - Investing.com Canada
Krystal Biotech, Inc. SEC 10-Q Report - TradingView
Krystal Biotech's Q2 revenue rises 37% to $96 mln - MarketScreener
Krystal Biotech, Inc. Q2 Profit Advances, But Misses Estimates - Nasdaq
Press Release: Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results - 富途牛牛
What drives Krystal Biotech Inc. stock priceGrow your portfolio with growth-oriented stocks - Jammu Links News
Is Krystal Biotech Inc. a good long term investmentUnlock real-time stock alerts for quick profits - Jammu Links News
How volatile is Krystal Biotech Inc. stock compared to the marketTrack emerging stocks with high growth potential - Jammu Links News
What are analysts’ price targets for Krystal Biotech Inc. in the next 12 monthsInvest smarter with expert stock recommendations - Jammu Links News
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):